Activating PIK3CA mutations in adipose-derived stem cells drive mutant-like phenotypes of wild-type cells in macrodactyly by Xiao Zhang, Yating Yin, Zhibo Wang, Yongkang Jiang, Aiping Yu, Xinyi Dai, Xiaoli Wang, Xuesong Guo, Hailei Mao, Bin Wang

“…Due to the somatic mosaicism, the affected tissues comprise a mixture of mutant and wild-type cells. However, how PIK3CA mutated ADSCs influence adjacent wild-type cells in macrodactyly remains poorly understood. …”
Get full text

In Silico Discovery of a Novel Potential Allosteric PI3Kα Inhibitor Incorporating 3-(2-Chloro-5-fluorophenyl)isoindolin-1-one to Target Head and Neck Squamous Cell Carcinoma by Wenqing Jia, Xianchao Cheng

“…PI3Kα allosteric inhibitors demonstrate therapeutic potential as both monotherapy and combination therapy, particularly in patients with <i>PIK3CA</i> mutations or resistance to immunotherapy, through the precise targeting of mutant PI3Kα. …”
Get full text

Frequency and effects of mutations in the KRAS gene on the survival of patients after surgical treatment of intrahepatic cholangiocarcinoma by B. N. Gurmikov, D. V. Kalinin, I. G. Nikitin, T. A. Zhinzhilo, A. N. Shipilova, A. V. Chzhao

“…Regarding the relapse-free survival rate in the groups of patients with the mutant and wild type of the KRAS gene, no significant differences were found.Conclusion. …”
Get full text

Differential Responses to Targeted Therapies in Non-Small Cell Lung Cancer: A Comparative Analysis of Outcomes in Patients with Single EGFR Mutation and Concurrent Gene Alterations by Le LT, Nguyen NV, Trinh HL, Van Le Q, Dao THT, Nguyen Ngoc S, Van LD, Thi Nguyen T

“…Among 43 patients with concurrent mutations, those with ALK mutations had the longest PFS (13.43 months), followed by PIK3CA (11.00 months), while MET alterations showed the shortest PFS (4.77 months).Conclusion: Concurrent gene alterations in EGFR-mutant NSCLC are associated with reduced efficacy of EGFR-TKIs. …”
Get full text

Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium anal... by Letizia Pontolillo, Andrew A. Davis, Lorenzo Gerratana, Arielle J. Medford, Judy Wang, Eleonora Nicolo’, Katherine Clifton, Marko Velimirovic, Surbhi Warrior, Emily Podany, Eleni Andreopoulou, Mara Serena Serafini, Laura Munoz-Arcos, Elisabetta Molteni, Marla Lipsyc-Sharf, Caterina Gianni, Nadia Bayou, Charles S. Dai, Diana Giannarelli, Emilio Bria, Cynthia X. Ma, Aditya Bardia, Carolina Reduzzi, Massimo Cristofanilli

“…Among 93 patients previously treated with CDK4/6i, PIK3CA (37.6%), ESR1 (46.2%) and TP53 (31.2%) were the most altered genes. …”
Get full text